Saltar al contenido
Merck

SHC201

Sigma-Aldrich

MISSION® TRC2 pLKO.5-puro Empty Vector Control Plasmid DNA

Contains no shRNA insert

Sinónimos:

MISSION® Control Vectors

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Número MDL:
Código UNSPSC:
41106609
NACRES:
NA.51

Línea del producto

MISSION®

concentración

500 ng/μL in TE buffer; DNA (10μg of plasmid DNA)

Condiciones de envío

dry ice

temp. de almacenamiento

−20°C

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

The MISSION TRC2 Control Vector pLKO-puro is a lentivirus plasmid vector. This vector is in the TRC2 pLKO-puro plasmid backbone, which contains the WPRE. The vector does not contain an shRNA insert and is useful as a negative control in experiments using the TRC2 MISSION shRNA library clones. This allows one to examine the effect of transfection on gene expression and interpret the knockdown effect seen with shRNA clones.

Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids (SHP001). The TRC2 pLKO-puro Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.

Aplicación

MISSION® TRC2 pLKO.5-puro Empty Vector Control Plasmid DNA has been used in:
  • CRISPR library generation
  • Viral constructs
  • Plasmid construction
  • CRISPR/Cas9-mediated knockouts.

Small interfering RNAs (siRNAs) expressed from short hairpin RNAs (shRNAs) are a powerful way to mediate gene specific RNA interference (RNAi) in mammalian cells. The MISSION product line is based on a viral vector-based RNAi library against annotated mouse and human genes. shRNAs that generate siRNAs intracellularly are expressed from amphotropic lentivirus viral particles, allowing screening in a wide range of mammalian cell lines. In these cell lines, MISSION shRNA clones permit rapid, cost efficient loss-of-function and genetic interaction screens.
To see more application data, protocols, vector maps visit sigma.com/shrna.

Información legal

Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense.
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Código de clase de almacenamiento

12 - Non Combustible Liquids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
Dompe N, et al.
PLoS ONE, 13(6), e0199264-e0199264 (2018)
Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia.
Cuellar TL, et al.
The Journal of Cell Biology (2017)
Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs.
Sahu N, et al.
Nature Communications, 7, 12351-12351 (2016)
Xingju Zhang et al.
Oncogene, 39(40), 6354-6369 (2020-08-29)
In patients with lung cancer, myeloid-derived suppressor cells (MDSCs) have been reported to be significantly increased. Tumor-derived exosomes (TDEs) from various cancers played a critical role in MDSC induction. However, studies on the molecular mechanism underlying MDSC expansion induced by
Janet Lau et al.
Nature communications, 8, 14572-14572 (2017-02-22)
Expression of PD-L1, the ligand for T-cell inhibitory receptor PD-1, is one key immunosuppressive mechanism by which cancer avoids eradication by the immune system. Therapeutic use of blocking antibodies to PD-L1 or its receptor PD-1 has produced unparalleled, durable clinical

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico